TY - JOUR
T1 - Possible involvement of acetylcholine-mediated inflammation in airway diseases
AU - Koarai, Akira
AU - Ichinose, Masakazu
N1 - Funding Information:
AK received a research grant from Terumo Foundation for Life Sciences and Arts . MI received lecture fees from Nippon Boehringer Ingelheim, Kyorin and Novartis Pharma.
Funding Information:
AK received a research grant from Terumo Foundation for Life Sciences and Arts. MI received lecture fees from Nippon Boehringer Ingelheim, Kyorin and Novartis Pharma.
Publisher Copyright:
© 2018 Japanese Society of Allergology
PY - 2018/10
Y1 - 2018/10
N2 - Inhaled bronchodilator treatment with a long acting muscarinic antagonist (LAMA) reduces symptoms and the risk of exacerbations in COPD and asthma. However, increasing evidence from cell culture and animal studies suggests that anti-muscarinic drugs could also possess anti-inflammatory effects. Recent studies have revealed that acetylcholine (ACh) can be synthesized and released from both neuronal and non-neuronal cells, and the released ACh can potentiate airway inflammation and remodeling in airway diseases. However, these anti-inflammatory effects of anti-muscarinic drugs have not yet been confirmed in COPD and asthma patients. This review will focus on recent findings about the possible involvement of ACh in airway inflammation and remodeling, and the anti-inflammatory effect of anti-muscarinic drugs in airway diseases. Clarifying the acetylcholine-mediated inflammation could provide insights into the mechanisms of airway diseases, which could lead to future therapeutic strategies for inhibiting the disease progression and exacerbations.
AB - Inhaled bronchodilator treatment with a long acting muscarinic antagonist (LAMA) reduces symptoms and the risk of exacerbations in COPD and asthma. However, increasing evidence from cell culture and animal studies suggests that anti-muscarinic drugs could also possess anti-inflammatory effects. Recent studies have revealed that acetylcholine (ACh) can be synthesized and released from both neuronal and non-neuronal cells, and the released ACh can potentiate airway inflammation and remodeling in airway diseases. However, these anti-inflammatory effects of anti-muscarinic drugs have not yet been confirmed in COPD and asthma patients. This review will focus on recent findings about the possible involvement of ACh in airway inflammation and remodeling, and the anti-inflammatory effect of anti-muscarinic drugs in airway diseases. Clarifying the acetylcholine-mediated inflammation could provide insights into the mechanisms of airway diseases, which could lead to future therapeutic strategies for inhibiting the disease progression and exacerbations.
KW - Airway inflammation
KW - Airway remodeling
KW - Anti-muscarinic drug
KW - Cholinergic regulation
KW - Non-neuronal ACh
UR - http://www.scopus.com/inward/record.url?scp=85044739447&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044739447&partnerID=8YFLogxK
U2 - 10.1016/j.alit.2018.02.008
DO - 10.1016/j.alit.2018.02.008
M3 - Review article
C2 - 29605098
AN - SCOPUS:85044739447
VL - 67
SP - 460
EP - 466
JO - Allergology International
JF - Allergology International
SN - 1323-8930
IS - 4
ER -